The FDA has authorized Motif Neurotech to begin clinical testing of its brain implant aimed at adults with treatment-resistant depression. The RESONATE study will assess safety, symptom improvement, ...

CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ...

Electrical transcutaneous neuromodulation (eTNM) of the peroneal nerve led to fewer side effects compared with solifenacin (Vesicare) in the treatment of overactive bladder, a randomized trial showed.

Major depressive disorder (MDD) and bipolar disorder are among the leading causes of disability worldwide. However, their pathophysiological mechanisms ...

Please provide your email address to receive an email when new articles are posted on . Artificial tears have long been the first option for patients with dry eye disease, but they only offer a ...

The company's FDA-cleared wearable uses personalized nerve stimulation to treat essential tremor and Parkinson's disease.

Essential tremor, one of the most common movement disorders, has long suffered from limited treatment options. Now, breakthroughs like ulixacaltamide and advances in surgical and noninvasive ...

For people living with depression, medication and therapy can be life-changing. But for others, those traditional options don ...

Abbott announced today that it has updated NeuroSphere, its app-driven neuromodulation therapy platform, with remote programming capabilities that will allow patients to speak with and receive ...

Please provide your email address to receive an email when new articles are posted on . Migraine pain relief was reported in more than 75% of users over 3 years. Treatment intensity increased by a ...